OpGen, Inc. Company Profile

20:26 EDT 17th March 2018 | BioPortfolio

OpGen® Technologies is a leading provider of genetic analysis services and systems. The company's proprietary "Optical Mapping" system (see technology) is used by academic and commercial organizations worldwide for applications including comparative genomics and genome sequence assembly/validation. Since Optical Mapping does not require sequence information it can be applied to a wide range of organisms not amenable to analysis by other genetic analysis systems. It is a particularly powerful method for detecting genome rearrangements, including the insertions, deletions, and translocations responsible for most variation in microorganisms. Optical Mapping is currently available to researchers worldwide as a fee-for-service.


510 Charmany DriveSuite 151
United States of America


Phone: 608.441.8100
Fax: 608.441.8101

News Articles [27 Associated News Articles listed on BioPortfolio]

Pricing of $12M stock offering announced by OpGen

A public offering of about 3.7 million units of common stock and common warrants was priced by OpGen at $3.25 each in hopes o -More- 

Thermo Fisher's PCR tech to be used in OpGen's gene panel tests

An agreement was reached by OpGen with Thermo Fisher Scientific to allow Thermo Fisher's real-time PCR technology to be used  -More- 

Active-Investors: Wired News - OpGen Announces Collaborator in Verification Study for Acuitas Tests

Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / has just released a free research report on OpGen, Inc. (NASDAQ: OPGN). If you want...

Nasdaq compliance regained by OpGen

Nasdaq notified OpGen that it regained its compliance with applicable listing standards.  -More- 

OpGen: Does This Ugly Screener Have Any Value?

OpGen raises $12M in private placement

OpGen Announces Execution of Reverse Stock Split

GAITHERSBURG, Md., Jan. 17, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announced today that it will implement a 1-for-25 reverse stock split of its common stock. The Company filed an amen...

OpGen Announces Closing of $12 Million Public Offering

GAITHERSBURG, Md., Feb. 07, 2018 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

OpGen, Inc.

OpGen® Technologies is a leading provider of genetic analysis services and systems. The company's proprietary "Optical Mapping" system (see technology) is used by academic and commercial organization...

More Information about "OpGen, Inc." on BioPortfolio

We have published hundreds of OpGen, Inc. news stories on BioPortfolio along with dozens of OpGen, Inc. Clinical Trials and PubMed Articles about OpGen, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of OpGen, Inc. Companies in our database. You can also find out about relevant OpGen, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record